No registrations found.
ID
Source
Brief title
Health condition
Parkinson’s disease and the GBA-PD subset of patients
Sponsors and support
Intervention
Outcome measures
Primary outcome
Based on multiple parameters, the following compound measurements are constructed:
- Parkinson's disease - Progression Rate lnventory (pD-pRl)
- GBA1 genotype and PD associated SNPs
- Parkinson's Risk Score (PRS)
- Rate of disease progression as rated by a clinical expert: Slow, Intermediate, Fast
The endpoints are the analyses of the associations between:
- genetic factors ând phenotypic factor
- genetic factors and the rate of disease progression as rated by a Movement Disorder Neurologist
- genetic factors and a data-driven algorithm based on phenotypic characteristics
Secondary outcome
N.A.
Background summary
This protocol is a follow-up on the previous study CHDR1707 (Toetsing online number: NL61137.056.17), titled
“Genetic screening in Parkinson’s Disease in order to identify patients who can participate in clinical trials with new
targeted therapies.” In this previous study, Parkinson’s patients throughout the Netherlands were genetically
screened for presence of mutations in the GBA1 gene and LRRK2 gene. In approximately 15% of all screened
patients, a mutation was found in the GBA1 gene. The current protocol aims to further characterize this subgroup
of patients with a GBA1 mutation, based on phenotype, as assessed by medical history, and on genotype, as
assessed by Parkinson’s disease related Single Nucleotide Polymorphism (SNP) analysis. The goal of this study
is to exploratively investigate whether clinical and genetic factors may contribute to the rate of clinical progression
in patients with Parkinson’s disease associated with a GBA1 mutation in the gene encoding GCase (GBA-PD)
Study objective
- To determine the relationship between phenotypic and genetic characteristics of GBA-PD patients. Phenotypic characteristics will be obtained by patient dossier review. Genetic characteristics of the GBA1 gene and a panel of SNP’s (gene markers), previously associated with risk or progression of idiopathic Parkinson’s disease, will be assessed.
- To determine the correlation between genetic characteristics (as described above) and the estimated disease progression rating (Fast, Intermediate, Slow) by a Movement Disorders Neurologist, based on retrospective phenotypic characteristics (as described above).
o lnter-rater correlation between Movement Disorders Neurologists will be determined in their rating of disease progression.
- To determine the correlation between genetic characteristics (as described above) and a data-driven algorithm based on phenotypic characteristics (as described above).
Study design
N.A. Observational study of hospital records and genotype records of PD patients (of CHDR1707 study )
Inclusion criteria
• Signed informed consent prior to any study-mandated procedure.
• Minimum age of 18 years.
• Clinical diagnosis of Parkinson’s disease at least 6 months prior to screening, confirmed by a Movement Disorder’s Neurologist.
• Mutation(s) in the glucocerebrosidase GBA1 gene. Reference Appendix A for a list of GBA1 mutations.
Exclusion criteria
• N.A.
Design
Recruitment
IPD sharing statement
Followed up by the following (possibly more current) registration
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| NTR-new | NL7717 |
| CCMO | NL67297.056.18 |
| OMON | NL-OMON46323 |